AbbVie (NYSE: ABBV) could be the poster child for how to effectively navigate a patent cliff. When Abbott Labs spun off ...

As Stelara biosimilars chip away at sales in Europe and off-brand rivals start to grace the stage in the U.S., Johnson & ...